{"id":"injectable-clostridial-collagenase","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site pain or swelling"},{"rate":null,"effect":"Bruising or hematoma"},{"rate":null,"effect":"Allergic reaction"},{"rate":null,"effect":"Tendon rupture (rare)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Clostridial collagenase is a protease enzyme derived from Clostridium histolyticum that specifically degrades collagen types I and III, the primary structural components of fibrotic tissue. When injected directly into pathological collagen deposits, it enzymatically cleaves the collagen matrix, weakening the tissue architecture and enabling manual manipulation or passive stretching to restore mobility and function.","oneSentence":"Injectable clostridial collagenase breaks down collagen in fibrotic tissue, allowing mechanical disruption of contractures and scar tissue.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:40:10.986Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Dupuytren's contracture"},{"name":"Peyronie's disease"}]},"trialDetails":[{"nctId":"NCT05777031","phase":"PHASE4","title":"Safety and Efficacy of Collagenase Clostridium Histolyticum After Prior Intralesional PRP for Peyronie's Disease","status":"RECRUITING","sponsor":"University of Miami","startDate":"2023-10-02","conditions":"Peyronie Disease, Sexual Dysfunctions, Psychological, Genital Diseases, Male","enrollment":22},{"nctId":"NCT06065436","phase":"NA","title":"Concurrent Low Intensity Shockwave Therapy on Collagenase Clostridium Histolyticum for Peyronie's Disease","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2024-01-19","conditions":"Peyronie Disease, Erectile Dysfunction","enrollment":60},{"nctId":"NCT06169319","phase":"PHASE2","title":"A Study to Assess Collagenase Clostridium Histolyticum (CCH) in the Treatment of Plantar Fasciitis (PFA)","status":"COMPLETED","sponsor":"Endo Pharmaceuticals","startDate":"2024-01-03","conditions":"Plantar Fasciitis","enrollment":231},{"nctId":"NCT03406338","phase":"PHASE4","title":"Fasciectomy vs Collagenase Injection in Recurrent Dupuytren Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"Region Skane","startDate":"2018-03-20","conditions":"Dupuytren Disease of Finger","enrollment":60},{"nctId":"NCT03192020","phase":"PHASE4","title":"Trial Comparing Treatment Strategies in Dupuytren's Contracture","status":"ACTIVE_NOT_RECRUITING","sponsor":"Tampere University","startDate":"2017-09-15","conditions":"Dupuytren Contracture","enrollment":302},{"nctId":"NCT05419505","phase":"PHASE2","title":"Study of Different Interventions to Reduce Bruising Following CCH-Aaes Treatment for Cellulite of the Buttocks","status":"COMPLETED","sponsor":"Endo Pharmaceuticals","startDate":"2022-06-15","conditions":"Edematous Fibrosclerotic Panniculopathy, Cellulite","enrollment":91},{"nctId":"NCT04874870","phase":"PHASE3","title":"Effectiveness of Splinting After Collagenase Injection","status":"COMPLETED","sponsor":"Foundation for Orthopaedic Research and Education","startDate":"2021-07-12","conditions":"Dupuytren Contracture, Dupuytren's Disease","enrollment":80},{"nctId":"NCT06649539","phase":"PHASE4","title":"Delayed Dose Collagenase Clostridium Histolyticum (CCH) Protocol for Men With Peyronie's Disease","status":"RECRUITING","sponsor":"Charitable Union for the Research and Education of Peyronie's Disease","startDate":"2024-10-11","conditions":"Peyronie Disease","enrollment":40},{"nctId":"NCT04786106","phase":"PHASE4","title":"Investigation of Surgery, Collagenase, and Restorex for the Improvement of Peyronie's","status":"ACTIVE_NOT_RECRUITING","sponsor":"Charitable Union for the Research and Education of Peyronie's Disease","startDate":"2020-12-30","conditions":"Peyronie's Disease","enrollment":40},{"nctId":"NCT05108558","phase":"PHASE4","title":"Efficacy of a Novel CCH Protocol for PD Among Prior Non-responders","status":"ACTIVE_NOT_RECRUITING","sponsor":"Charitable Union for the Research and Education of Peyronie's Disease","startDate":"2021-09-20","conditions":"Peyronie's Disease","enrollment":40},{"nctId":"NCT06330545","phase":"NA","title":"Radiation Therapy for Dupuytren's Contracture Following Non-Surgical Release","status":"RECRUITING","sponsor":"Dartmouth-Hitchcock Medical Center","startDate":"2024-09-16","conditions":"Dupuytren Contracture","enrollment":95},{"nctId":"NCT02948842","phase":"PHASE2","title":"Clostridium Histolyticum Collagenase Injection for Urethral Disease","status":"COMPLETED","sponsor":"University of South Florida","startDate":"2020-05-22","conditions":"Urethral Stricture","enrollment":5},{"nctId":"NCT05646602","phase":"NA","title":"Focused Shock Wave Therapy Outcomes in Peyronie's Disease and Erectile Dysfunction","status":"WITHDRAWN","sponsor":"Mayo Clinic","startDate":"2023-03","conditions":"Peyronie Disease, Penile Curvature, Erectile Dysfunction","enrollment":""},{"nctId":"NCT03898661","phase":"EARLY_PHASE1","title":"Collagenase Clostridium Histolyticum for Refractory Iatrogenic Esophageal Strictures","status":"TERMINATED","sponsor":"University Hospital, Ghent","startDate":"2019-03-29","conditions":"Stricture, Esophageal Stricture, Anastomotic","enrollment":2},{"nctId":"NCT03632993","phase":"PHASE2","title":"Injection Techniques of Collagenase Clostridium Histolyticum (CCH) for the Treatment of EFP (Cellulite)","status":"COMPLETED","sponsor":"Endo Pharmaceuticals","startDate":"2018-09-18","conditions":"Edematous Skin","enrollment":64},{"nctId":"NCT02725528","phase":"PHASE3","title":"Evaluation of Xiaflex: Trial of Effectivenss iN Dupuytren's","status":"COMPLETED","sponsor":"McMaster University","startDate":"2017-07-08","conditions":"Dupuytren's Disease","enrollment":22},{"nctId":"NCT05309525","phase":"PHASE4","title":"Effect of Oral TXA on Buttock Bruising Post CCH Injections in Adult Females","status":"COMPLETED","sponsor":"Luxurgery","startDate":"2022-04-22","conditions":"Cellulite","enrollment":17},{"nctId":"NCT05249257","phase":"","title":"Durability and Safety of CCH With Two Different Injection Techniques in Cellulite With Laxity","status":"COMPLETED","sponsor":"Endo Pharmaceuticals","startDate":"2022-01-25","conditions":"Cellulite, Laxity; Skin, Edematous Fibrosclerotic Panniculopathy","enrollment":20},{"nctId":"NCT04580303","phase":"PHASE2","title":"CCH Treatment of Cellulite in the Presence of Dermal Laxity With Comparison Between Two (2) Different Injection Techniques","status":"COMPLETED","sponsor":"Endo Pharmaceuticals","startDate":"2020-10-01","conditions":"Edematous Fibrosclerotic Panniculopathy, Cellulite, Laxity; Skin","enrollment":35},{"nctId":"NCT02647619","phase":"PHASE4","title":"Dupuytren´s Disease Study. Primary Disease, MCP Joint, Xiapex, PNF","status":"COMPLETED","sponsor":"University Hospital, Akershus","startDate":"2013-10","conditions":"Dupuytren Contracture","enrollment":80},{"nctId":"NCT04236635","phase":"PHASE2","title":"Histopathology Following CCH Injection","status":"COMPLETED","sponsor":"Endo Pharmaceuticals","startDate":"2019-12-20","conditions":"Characteristics of Subcutaneous Tissue","enrollment":10},{"nctId":"NCT05026216","phase":"PHASE4","title":"To Assess the Effectiveness of Multiple Dose, Multiple Concentrations of Qwo, for the Treatment of Mild to Moderate Cellulite.","status":"COMPLETED","sponsor":"DMR Research, PLLC","startDate":"2021-03-29","conditions":"Cellulite","enrollment":5},{"nctId":"NCT03329989","phase":"PHASE2","title":"Safety and Effectiveness of EN3835 in the Treatment of EFP in Women","status":"COMPLETED","sponsor":"Endo Pharmaceuticals","startDate":"2017-11-17","conditions":"Edematous Fibrosclerotic Panniculopathy, Cellulite","enrollment":158},{"nctId":"NCT03675685","phase":"PHASE1","title":"Safety and Pharmacokinetics of a Single Dose of CCH (3.36 mg) in Subjects With EFP","status":"COMPLETED","sponsor":"Endo Pharmaceuticals","startDate":"2018-09-18","conditions":"Edematous Fibrosclerotic Panniculopathy","enrollment":12},{"nctId":"NCT02889848","phase":"PHASE1","title":"Safety and Tolerability of Collagenase Clostridium Histolyticum (EN3835) to Treat Uterine Leiomyoma (Fibroids)","status":"COMPLETED","sponsor":"Advance Biofactures Corporation","startDate":"2016-10-27","conditions":"Fibroids, Uterine, Leiomyoma","enrollment":15},{"nctId":"NCT00528840","phase":"PHASE3","title":"Safety and Efficacy Study of AA4500 (XIAFLEX™, Proposed Name) in the Treatment of Advanced Dupuytren's Disease","status":"COMPLETED","sponsor":"Endo Pharmaceuticals","startDate":"2007-10","conditions":"Advanced Dupuytren's Disease","enrollment":201},{"nctId":"NCT00528606","phase":"PHASE3","title":"AA4500 (XIAFLEX™, Proposed Name) in the Treatment of Dupuytren's Contracture","status":"COMPLETED","sponsor":"Endo Pharmaceuticals","startDate":"2007-08","conditions":"Dupuytren's Contracture","enrollment":308},{"nctId":"NCT00533273","phase":"PHASE3","title":"Non-US Study of AA4500 (XIAFLEX™, Proposed Name) in the Treatment of Advanced Dupuytren's Disease","status":"COMPLETED","sponsor":"Endo Pharmaceuticals","startDate":"2007-08","conditions":"Advanced Dupuytren's Disease","enrollment":66},{"nctId":"NCT02724644","phase":"PHASE2","title":"EN3835 for the Treatment of Edematous Fibrosclerotic Panniculopathy (Commonly Known as Cellulite)","status":"COMPLETED","sponsor":"Endo Pharmaceuticals","startDate":"2016-02","conditions":"Edematous Fibrosclerotic Panniculopathy, Cellulite","enrollment":375},{"nctId":"NCT00755222","phase":"PHASE2","title":"The Safety and Effectiveness of AA4500 in Subjects With Peyronie's Disease","status":"COMPLETED","sponsor":"Endo Pharmaceuticals","startDate":"2008-08","conditions":"Peyronie's Disease","enrollment":147},{"nctId":"NCT01674634","phase":"PHASE3","title":"Safety and Efficacy of Two Concurrent Injections of AA4500 in Adult Subjects With Multiple Dupuytren's Contractures","status":"COMPLETED","sponsor":"Endo Pharmaceuticals","startDate":"2012-09","conditions":"Dupuytren's Contracture","enrollment":715},{"nctId":"NCT01498640","phase":"PHASE4","title":"Retreatment of Recurrent Dupuytren's Contractures","status":"COMPLETED","sponsor":"Endo Pharmaceuticals","startDate":"2012-03","conditions":"Dupuytren's Disease","enrollment":52},{"nctId":"NCT02006719","phase":"PHASE2","title":"Clinical Study for the Treatment of Adhesive Capsulitis of the Shoulder","status":"COMPLETED","sponsor":"Endo Pharmaceuticals","startDate":"2013-11","conditions":"Adhesive Capsulitis, Frozen Shoulder","enrollment":322},{"nctId":"NCT01221597","phase":"PHASE3","title":"Study of AA4500 in the Treatment of Peyronie's Disease","status":"COMPLETED","sponsor":"Endo Pharmaceuticals","startDate":"2010-09","conditions":"Peyronie's Disease","enrollment":418},{"nctId":"NCT01483963","phase":"PHASE2","title":"AA4500 for the Treatment of Adhesive Capsulitis of the Shoulder","status":"COMPLETED","sponsor":"Endo Pharmaceuticals","startDate":"2011-11","conditions":"Adhesive Capsulitis, Frozen Shoulder","enrollment":50},{"nctId":"NCT00528931","phase":"PHASE1","title":"A Pharmacokinetic Study of AA4500 (XIAFLEX™, Proposed Name) in Subjects With Dupuytren's Contracture","status":"COMPLETED","sponsor":"Endo Pharmaceuticals","startDate":"2007-09","conditions":"Dupuytren's Contracture","enrollment":16},{"nctId":"NCT01221623","phase":"PHASE3","title":"Study of AA4500 in the Treatment of Peyronie's Disease","status":"COMPLETED","sponsor":"Endo Pharmaceuticals","startDate":"2010-10","conditions":"Peyronie's Disease","enrollment":418},{"nctId":"NCT01407068","phase":"PHASE3","title":"Administration of Two Injections for Multiple Dupuytren's Contractures","status":"COMPLETED","sponsor":"Endo Pharmaceuticals","startDate":"2011-09","conditions":"Dupuytren's Contracture","enrollment":60},{"nctId":"NCT01685437","phase":"PHASE3","title":"A Phase 3, Open-label Study of the Safety and Effectiveness of AA4500 Administered Twice Per Treatment Cycle for up to Four Treatment Cycles (2 x 4) in Men With Peyronie's Disease","status":"COMPLETED","sponsor":"Endo Pharmaceuticals","startDate":"2012-09","conditions":"Peyronie's Disease","enrollment":189},{"nctId":"NCT02193828","phase":"PHASE2","title":"Phase 2a Dose-Ranging Study to Evaluate Safety and Effectiveness of AA4500 in Treatment of Dupuytren's Disease Nodules","status":"COMPLETED","sponsor":"Endo Pharmaceuticals","startDate":"2014-07","conditions":"Dupuytren's Disease","enrollment":76},{"nctId":"NCT01243411","phase":"PHASE3","title":"A Study of AA4500 in Men With Peyronie's Disease","status":"COMPLETED","sponsor":"Endo Pharmaceuticals","startDate":"2010-11","conditions":"Peyronie's Disease","enrollment":348},{"nctId":"NCT01430169","phase":"PHASE2","title":"Pharmacokinetics of a Single Treatment Cycle of AA4500 0.58 mg in Men With Peyronie's Disease","status":"COMPLETED","sponsor":"Endo Pharmaceuticals","startDate":"2011-09","conditions":"Peyronie's Disease","enrollment":20},{"nctId":"NCT02249052","phase":"PHASE2","title":"Double Blind Study to Evaluate the Efficacy of Collagenase Histolyticum in the Treatment of Lipoma","status":"COMPLETED","sponsor":"Gerut, Zachary, M.D.","startDate":"2014-08","conditions":"Lipoma","enrollment":19},{"nctId":"NCT03000114","phase":"PHASE4","title":"Collagenase Injection vs Percutaneous Needle Aponeurotomy for Dupuytren's Disease","status":"UNKNOWN","sponsor":"University of Calgary","startDate":"2016-01","conditions":"Dupuytren Contracture, Dupuytren's Disease of Finger","enrollment":334},{"nctId":"NCT02301078","phase":"","title":"Short-term Function and Pain After Treatment for Dupuytren's Disease","status":"UNKNOWN","sponsor":"Sunnybrook Health Sciences Centre","startDate":"2014-07","conditions":"Dupuytren Disease","enrollment":60},{"nctId":"NCT01613313","phase":"PHASE2","title":"A Dose Escalation Study Using Collagenase Clostridium Histolyticum in the Treatment of Lipoma","status":"COMPLETED","sponsor":"Zachary Gerut","startDate":"2012-05","conditions":"Lipoma","enrollment":14},{"nctId":"NCT01538017","phase":"NA","title":"Injectable Collagenase and Percutaneous Needle Fasciotomy for Dupuytren's Contracture","status":"COMPLETED","sponsor":"Jeppe Lange, MD","startDate":"2012-02","conditions":"Dupuytrens Contracture","enrollment":50},{"nctId":"NCT00261209","phase":"PHASE1, PHASE2","title":"Collagenase in the Treatment of Zone II Flexor Tendon Adhesions in the Hand","status":"COMPLETED","sponsor":"Stony Brook University","startDate":"2005-01","conditions":"Adhesion of Flexor Tendon of Hand","enrollment":3},{"nctId":"NCT01265420","phase":"PHASE4","title":"Efficacy and Safety of Xiaflex Injection for Treatment of Dupuytren's Contracture of the Thumb","status":"COMPLETED","sponsor":"Indiana Hand to Shoulder Center","startDate":"2010-12","conditions":"Dupuytren's Contracture","enrollment":7},{"nctId":"NCT01226121","phase":"PHASE4","title":"Safety and Efficacy of Delayed Manipulation After Xiaflex Treatment in Subjects With Dupuytren's Contracture","status":"TERMINATED","sponsor":"Indiana Hand to Shoulder Center","startDate":"2010-12","conditions":"Dupuytren's Disease","enrollment":37},{"nctId":"NCT01776892","phase":"PHASE3","title":"Collagenase and Needle Aponeurotomy: Single Modality Versus Combination Treatment for Dupuytren's Disease","status":"WITHDRAWN","sponsor":"University of Alberta","startDate":"2013-05","conditions":"Dupuytren Contracture","enrollment":""},{"nctId":"NCT01229436","phase":"PHASE3","title":"Treatment Of Dupuytren's Contracture With Collagenase Clostridium Histolyticum Injection (Xiapex)","status":"COMPLETED","sponsor":"Pfizer","startDate":"2010-12","conditions":"Dupuytren's Contracture","enrollment":254},{"nctId":"NCT00260429","phase":"PHASE3","title":"Collagenase in the Treatment of Dupuytrens Disease","status":"COMPLETED","sponsor":"Stony Brook University","startDate":"2003-06","conditions":"Dupuytren's Disease","enrollment":38},{"nctId":"NCT01237964","phase":"PHASE2","title":"Injectable Collagenase For Burns' Associated Contracture","status":"UNKNOWN","sponsor":"Sheba Medical Center","startDate":"2011-03","conditions":"Burn's Associated Contracture","enrollment":10}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":32,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Xiaflex"],"phase":"marketed","status":"active","brandName":"Injectable clostridial collagenase","genericName":"Injectable clostridial collagenase","companyName":"Indiana Hand to Shoulder Center","companyId":"indiana-hand-to-shoulder-center","modality":"Biologic","firstApprovalDate":"","aiSummary":"Injectable clostridial collagenase is a hydrolytic enzyme that targets collagen, classified as a HYDROLYTIC ENZYME. It has been studied for the treatment of Dupuytren's Contracture, Urethral Stricture, and Cellulite in clinical trials.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}